Concizumab is in development to prevent bleeding episodes in haemophilia A (HA) or haemophilia B (HB), with or without inhibitors. Haemophilia is an inherited disorder caused by lack of blood clotting factor which makes patients prone to excessive and uncontrolled bleeding. HA and HB are treated with replacement factor VIII (FVIII) and factor IX (FIX) to restore blood clotting and prevent bleeding. A major challenge to treatment of HA/HB is that patients can develop antibodies, called inhibitors, which make treatment less effective.
Concizumab for treating haemophilia A and haemophilia B
Concizumab is in development to prevent bleeding episodes in haemophilia A (HA) or haemophilia B (HB), with or without inhibitors. Haemophilia is an inherited disorder caused by lack of blood clotting factor which makes patients prone to excessive and uncontrolled bleeding.